- Borderline tumours of the ovary: Common practice in the Netherlands
- Accuracy of Intraoperative Computed Tomography in Deep Brain Stimulation-A Prospective Noninferiority Study
- BRCA2 deficiency instigates cGAS-mediated inflammatory signaling and confers sensitivity to tumor necrosis factor-alpha-mediated cytotoxicity
- Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of CHRM1 and CHRM2 muscarinic receptors
- The (R)-enantiomer of the 6-chromanol derivate SUL-121 improves renal graft perfusion via antagonism of the α-adrenoceptor
- Judging residents' performance: a qualitative study using grounded theory
- Twenty-nine Cases of Enterovirus-D68-associated Acute Flaccid Myelitis in Europe 2016 A Case Series and Epidemiologic Overview
- STAT3 Regulates the Onset of Oxidant-Induced Senescence in Lung Fibroblasts
- Trans-ethnic kidney function association study reveals putative causal genes and effects on kidney-specific disease aetiologies
- Evaluation of Macitentan in Patients With Eisenmenger Syndrome Results From the Randomized, Controlled MAESTRO Study
Most Used Journals
Bio-inspired pulmonary surfactant-modified nanogels: a promising siRNA delivery system.
J Control Release. 2015 Mar 16;
Authors: De Backer L, Braeckmans K, Stuart MC, Demeester J, De Smedt SC, Raemdonck K
Inhalation therapy with small interfering RNA (siRNA) is a promising approach in the treatment of pulmonary disorders. However, clinical translation is severely limited by the lack of suitable delivery platforms. In this study, we aim to address this limitation by designing a novel bioinspired hybrid nanoparticle with a core-shell nanoarchitecture, consisting of a siRNA-loaded dextran nanogel (siNG) core and a pulmonary surfactant (Curosurf®) outer shell. The decoration of siNGs with a surfactant shell enhances the colloidal stability and prevents siRNA release in the presence of competing polyanions, which are abundantly present in biofluids. Additionally, the impact of the surfactant shell on the biological efficacy of the siNGs is determined in lung cancer cells. The presence of the surfactants substantially reduces the cellular uptake of siNGs. Remarkably, the lowered intracellular dose does not impede the gene silencing effect, suggesting a crucial role of the pulmonary surfactant in the intracellular processing of the nanoparticles. In order to surmount the observed reduction in cellular dose, folate is incorporated as a targeting ligand in the pulmonary surfactant shell to incite receptor-mediated endocytosis. The latter substantially enhances both cellular uptake and gene silencing potential, achieving efficient knockdown at siRNA concentrations in the low nanomolar range.
PMID: 25791835 [PubMed – as supplied by publisher]